Stockreport

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen, Inc.  (OCGN) 
PDF Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. [Read more]